EL MONTE, Calif. — Fulgent Genetics, Inc. (NASDAQ: FLGT) on Wednesday announced it has completed its previously disclosed acquisition of Bako Diagnostics, a pathology laboratory, and StrataDx, a dermatopathology laboratory, advancing the company’s expansion in specialty diagnostics.
The transaction, first announced on December 22, 2025, includes the acquisition of certain assets of Bako Diagnostics and the full acquisition of StrataDx for a combined purchase price of approximately $56.9 million in cash, subject to post-closing adjustments.
The deal strengthens Fulgent’s laboratory services portfolio by adding capabilities in anatomic pathology, molecular genetic testing, and dermatopathology, as the company continues its push toward becoming a fully integrated precision medicine provider.
Piper Sandler & Co. served as exclusive financial advisor to Fulgent, while Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as legal counsel. EV Health Partners advised Consonance Capital Partners, Bako Diagnostics, and StrataDx, with Latham & Watkins LLP serving as legal counsel.
Fulgent operates a technology-driven laboratory services business that provides technical testing services and physician interpretation of results. The company also maintains a therapeutic development division focused on creating cancer treatments using a nanoencapsulation and targeted therapy platform designed to improve drug delivery and effectiveness.
Bako Diagnostics is a national provider of specialty laboratory testing services, offering anatomic pathology, molecular genetic testing, and immuno-histochemical testing for peripheral neuropathy, with a focus on physician support and specialized expertise.
StrataDx, based in Lexington, Massachusetts, specializes in dermatopathology and advanced diagnostic testing for a wide range of skin conditions, including melanocytic and soft tissue lesions, dermatoses, and lymphomas. The laboratory is led by dermatopathology experts and supported by board-certified oral pathologists with experience across multiple clinical specialties.
